Stockscreener 앱 받기
0.6614
6.95%
-0.0494
시간 외 거래:
.66
-0.0014
-0.21%
전일 마감가:
$0.7108
열려 있는:
$0.7057
하루 거래량:
652.96K
Relative Volume:
0.55
시가총액:
$192.89M
수익:
$54,000
순이익/손실:
$-210.26M
주가수익비율:
-0.8372
EPS:
-0.79
순현금흐름:
$-159.01M
1주 성능:
-0.56%
1개월 성능:
+13.16%
6개월 성능:
-52.76%
1년 성능:
-78.46%
1일 변동 폭
$0.6506
$0.7057
1주일 범위
$0.6441
$0.7326
52주 변동 폭
$0.5092
$3.2556
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
LYEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
0.6614 | 192.89M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Lyell Immunopharma (LYEL) Projected to Post Earnings on Wednesday - MarketBeat
Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - GlobeNewswire
LYELLyell Immunopharma, Inc. Latest Stock News & Market Updates - StockTitan
Cell Therapy Pioneer Lyell to Showcase Cancer Treatment Breakthroughs at Elite Investor Events - StockTitan
What Did We Find About Insider Trading At Lyell Immunopharma Inc (NASDAQ: LYEL)? - Stocks Register
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why - MSN
Following a 67% decline over last year, recent gains may please Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional owners - Simply Wall St
SG Americas Securities LLC Has $75,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Market Recap Check: Lyell Immunopharma Inc (LYEL)’s Negative Finish at 0.57, Up/Down -2.94 - The Dwinnex
Lyell Immunopharma Inc (LYEL) Stock: A Year of Market Fluctuations - The InvestChronicle
Take off with Lyell Immunopharma Inc (LYEL): Get ready for trading - SETE News
LYEL underperforms with a -0.98 decrease in share price - US Post News
Market Momentum Report: Lyell Immunopharma Inc (LYEL)’s Negative Close at 0.58 - The Dwinnex
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Lyell Immunopharma Faces Nasdaq delisting over share price - MSN
Lyell Immunopharma Faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma price target lowered to 60c from $1 at BofA - MSN
Lyell Immunopharma stock hits 52-week low at $0.58 - Investing.com India
Lyell to Highlight Vision for its Next-Generation CAR - GlobeNewswire
Lyell's IMPT-314 Cancer Therapy Shows 94% Response Rate, Plans Pivotal Trials for Lymphoma - StockTitan
Jane Street Group LLC Buys 111,917 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Barclays PLC Has $332,000 Stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL) - Yahoo Finance
State Street Corp Has $5.37 Million Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Cellares and Lyell to Evaluate Automated Manufacturing of Lyell' - GuruFocus.com
Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Shares Sold by Fmr LLC - Defense World
Fmr LLC Has $1.41 Million Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - MarketBeat
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround - Yahoo Finance
Lyell Immunopharma stock hits 52-week low at $0.85 By Investing.com - Investing.com Australia
Lyell Immunopharma stock hits 52-week low at $0.85 - Investing.com India
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial - StockTitan
Lyell Presents Positive Initial Clinical Data from the - GlobeNewswire
Form 424B5 Lyell Immunopharma, Inc. - StreetInsider.com
Intech Investment Management LLC Acquires New Shares in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
SEC Form S-3 filed by Lyell Immunopharma Inc. - Quantisnow
Lyell Immunopharma Reports Resignation of Board Member - Defense World
Lyell Immunopharma Director Hans bishop resigns - Investing.com
Lyell Immunopharma Director Hans bishop resigns By Investing.com - Investing.com Australia
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.45%
1.23%
자본화:
|
볼륨(24시간):